Literature DB >> 25234825

Assessment of myocardial infarct size with body surface potential mapping: validation against contrast-enhanced cardiac magnetic resonance imaging.

Minna M Kylmälä1,2, Teijo Konttila3, Paula Vesterinen1,2, Sari M Kivistö4, Kirsi Lauerma4, Mats Lindholm3, Heikki Väänänen3, Matti Stenroos3, Markku S Nieminen1, Helena Hänninen1, Lauri Toivonen1.   

Abstract

BACKGROUND: Assessment of myocardial infarct (MI) size is important for therapeutic and prognostic reasons. We used body surface potential mapping (BSPM) to evaluate whether single-lead electrocardiographic variables can assess MI size.
METHODS: We performed BSPM with 120 leads covering the front and back chest (plus limb leads) on 57 patients at different phases of MI: acutely, during healing, and in the chronic phase. Final MI size was determined by contrast-enhanced cardiac magnetic resonance imaging (DE-CMR) and correlated with various computed depolarization- and repolarization-phase BSPM variables. We also calculated correlations between BSPM variables and enzymatic MI size (peak CK-MBm).
RESULTS: BSPM variables reflecting the Q- and R wave showed strong correlations with MI size at all stages of MI. R width performed the best, showing its strongest correlation with MI size on the upper right back, there representing the width of the "reciprocal Q wave" (r = 0.64-0.71 for DE-CMR, r = 0.57-0.64 for CK-MBm, P < 0.0001). Repolarization-phase variables showed only weak correlations with MI size in the acute phase, but these correlations improved during MI healing. T-wave variables and the QRSSTT integral showed their best correlations with DE-CMR defined MI size on the precordial area, at best r = -0.57, P < 0.0001 in the chronic phase. The best performing BSPM variables could differentiate between large and small infarcts at all stages of MI.
CONCLUSIONS: Computed, single-lead electrocardiographic variables can estimate the final infarct size at all stages of MI, and differentiate large infarcts from small.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  body surface potential mapping; cardiac magnetic resonance imaging; electrocardiography; myocardial infarct size; myocardial infarction

Mesh:

Substances:

Year:  2014        PMID: 25234825      PMCID: PMC6931515          DOI: 10.1111/anec.12198

Source DB:  PubMed          Journal:  Ann Noninvasive Electrocardiol        ISSN: 1082-720X            Impact factor:   1.468


  33 in total

1.  Predicting recovery of myocardial function by electrocardiography after acute infarction.

Authors:  Minna M Kylmälä; Teijo Konttila; Paula Vesterinen; Mats Lindholm; Heikki Väänänen; Matti Stenroos; Markku S Nieminen; Helena Hänninen; Lauri Toivonen
Journal:  Ann Noninvasive Electrocardiol       Date:  2012-11-22       Impact factor: 1.468

2.  Size and transmural extent of first-time reperfused myocardial infarction assessed by cardiac magnetic resonance can be estimated by 12-lead electrocardiogram.

Authors:  Henrik Engblom; Erik Hedström; Einar Heiberg; Galen S Wagner; Olle Pahlm; Håkan Arheden
Journal:  Am Heart J       Date:  2005-11       Impact factor: 4.749

3.  Significance of T-wave amplitude and dynamics at the time of reperfusion in patients with acute ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.

Authors:  Jacob Thorsted Sørensen; Marc Aaron Murinson; Anne Kjer Kaltoft; Kjell Christer Nikus; Galen Strohm Wagner; Christian Juhl Terkelsen
Journal:  J Electrocardiol       Date:  2009 Nov-Dec       Impact factor: 1.438

4.  Myocardial damage and left ventricular dysfunction in patients with and without persistent negative T waves after Q-wave anterior myocardial infarction.

Authors:  K Sakata; H Yoshino; H Houshaku; Y Koide; M Yotsukura; K Ishikawa
Journal:  Am J Cardiol       Date:  2001-03-01       Impact factor: 2.778

5.  Persistent negative T waves in the infarct-related leads as an independent predictor of poor long-term prognosis after acute myocardial infarction.

Authors:  Patrizio Lancellotti; Paul L Gérard; Henri E Kulbertus; Luc A Piérard
Journal:  Am J Cardiol       Date:  2002-10-15       Impact factor: 2.778

6.  Transmural extent of acute myocardial infarction predicts long-term improvement in contractile function.

Authors:  K M Choi; R J Kim; G Gubernikoff; J D Vargas; M Parker; R M Judd
Journal:  Circulation       Date:  2001-09-04       Impact factor: 29.690

7.  Use of signals in the terminal QRS complex to identify patients with ventricular tachycardia after myocardial infarction.

Authors:  M B Simson
Journal:  Circulation       Date:  1981-08       Impact factor: 29.690

8.  Comparison of enzymatic and anatomic estimates of myocardial infarct size in man.

Authors:  D B Hackel; K A Reimer; R E Ideker; E M Mikat; T D Hartwell; C B Parker; E B Braunwald; M Buja; H K Gold; A S Jaffe
Journal:  Circulation       Date:  1984-11       Impact factor: 29.690

9.  Electrocardiographic measurement of infarct size after thrombolytic therapy.

Authors:  C P Juergens; C Fernandes; E T Hasche; S Meikle; G Bautovich; C A Currie; S B Freedman; R W Jeremy
Journal:  J Am Coll Cardiol       Date:  1996-03-01       Impact factor: 24.094

10.  Non-invasive arrhythmia risk evaluation in clinical environment.

Authors:  H Väänänen; P Korhonen; J Montonen; M Mäkijärvi; J Nenonen; L Oikarinen; K Simelius; L Toivonen; T Katila
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2000-12
View more
  2 in total

1.  Body Surface Potential Mapping: Contemporary Applications and Future Perspectives.

Authors:  Jake Bergquist; Lindsay Rupp; Brian Zenger; James Brundage; Anna Busatto; Rob S MacLeod
Journal:  Hearts (Basel)       Date:  2021-11-05

2.  Peak CK-MB has a strong association with chronic scar size and wall motion abnormalities after revascularized non-transmural myocardial infarction - a prospective CMR study.

Authors:  Pauli Pöyhönen; Minna Kylmälä; Paula Vesterinen; Sari Kivistö; Miia Holmström; Kirsi Lauerma; Heikki Väänänen; Lauri Toivonen; Helena Hänninen
Journal:  BMC Cardiovasc Disord       Date:  2018-02-08       Impact factor: 2.298

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.